[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-326981-105":59,"doc-detail-326981-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","moving-beyond-traditional-therapies-the-role-of-nanomedicines-in-lung-cancer-review","Moving beyond traditional therapies - the role of nanomedicines in lung cancer - Review","","Reviewing the global increase in lung cancer, the work contrasts conventional treatments with significant side effects, toxicity, and limited specificity. It explains how nanomedicine approaches can improve drug delivery to tumor sites, prolong drug half-life, and reduce harm to healthy tissues, thereby supporting earlier detection and targeted therapy. The review highlights active versus passive targeting strategies, outlines key mechanisms, and argues that multimodal, multi-target combination nanocomposites may enable more effective future clinical regimens.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/moving-beyond-traditional-therapies-the-role-of-nanomedicines-in-lung-cancer-review/326981/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/moving-beyond-traditional-therapies-the-role-of-nanomedicines-in-lung-cancer-review/326981.png","ImageObject",300,407,{"name":92,"@type":93},"Anda","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are conventional lung cancer therapies limited in effectiveness?","Question",{"text":112,"@type":113},"Conventional therapies show substantial side effects and toxicities and often lack specificity, with chemotherapy used in most cases but still presenting major drawbacks and resistance-related issues.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What advantages do nanomedicines provide for lung cancer treatment?",{"text":117,"@type":113},"Nanomedicines can enhance drug delivery to tumor sites, extend drug half-life, and reduce unintended toxic effects on healthy tissues, supporting earlier detection and more targeted therapy.",{"name":119,"@type":110,"acceptedAnswer":120},"How do active and passive targeting nanomedicine strategies differ?",{"text":121,"@type":113},"Active targeting focuses on a single target, which can yield unsatisfactory outcomes, while passive targeting often suffers from limited delivery rates; combining the two is suggested to improve concentration at target sites.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},326981,1790195538,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":4},962075006959,"https://ap-avatar.wpscdn.com/avatar/e0002397efbe92a78e?_k=1776741047341049297","TYPE Review  \nPUBLISHED 08 February 2024 DOI 10.3389/fphar.2024.1363346  \nOPEN ACCESS  \nEDITED BY  \nWangxiao He,  \nXi’an Jiaotong University, China  \nREVIEWED BY  \nMerve Karpuz,  \nIzmir Kâtip Çelebi University, Türkiye Aimin Jiang,  \nThe First Affiliated Hospital of Xi’an Jiaotong University, China  \n*CORRESPONDENCE  \nShaohui Wang,  \n [winter9091@163.com](winter9091@163.com)  \nRECEIVED 30 December 2023  \nACCEPTED 29 January 2024  \nPUBLISHED 08 February 2024  \nCITATION  \nZhang J, Li Y, Guo S, Zhang W, Fang B and Wang S (2024), Moving beyond traditional therapies: the role of nanomedicines in lung cancer.  \nFront. Pharmacol. 15:1363346 .  \ndoi: 10.3389/fphar.2024.1363346  \nCOPYRIGHT  \n© 2024 Zhang, Li, Guo, Zhang, Fang and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nMoving beyond traditional therapies: the role of nanomedicines in lung cancer  \nJingjing Zhang 1,2, Yanzhi Li 1, Sa Guo 3, Weifen Zhang 4, Bing Fang 2 and Shaohui Wang 3*  \n1Medical College of Qingdao Binhai University, Qingdao, China, 2The Affiliated Hospital of Qindao Binhai University (Qingdao Military-Cvil Integration Hospital), Qingdao, China, 3Ethnic Medicine Academic Heritage Innovation Research Center, Meishan Traditional Chinese Medicine Hospital, Chengdu University of Traditional Chinese Medicine, Chengdu, China, 4Medical College, Weifang University, Weifang, China  \nAmidst a global rise in lung cancer occurrences, conventional therapies continue to pose substantial side effects and possess notable toxicities while lacking specificity. Counteracting this, the incorporation of nanomedicines can notably enhance drug delivery at tumor sites, extend a drug’s half-life and mitigate inadvertent toxic and adverse impacts on healthy tissues, substantially influencing lung cancer ’s early detection and targeted therapy. Numerous studies signal that while the nano-characteristics of lung cancer nanomedicines play a pivotal role, further interplay with immune, photothermal, and genetic factors exist. This review posits that the progression towards multimodal combination therapies could potentially establish an efficacious platform for multimodal targeted lung cancer treatments. Current nanomedicines split into active and passive targeting. Active therapies focus on a single target, often with unsatisfactory results. Yet, developing combination systems targeting multiple sites could chart new paths in lung cancer therapy. Conversely, low drug delivery rates limit passive therapies. Utilizing the EPR effect to bind specific ligands on nanoparticles to tumor cell receptors might create a new regime combining active-passive targeting, potentially elevating the nanomedicines ’ concentration at target sites. This review collates recent advancements through the lens of nanomedicine ’s attributes for lung cancer therapeutics, the novel carrier classifications, targeted therapeutic modalities and their mechanisms, proposing that the emergence of multi-target nanocomposite therapeutics, combined active-passive targeting therapies and multimodal combined treatments will pioneer novel approaches and tools for future lung cancer clinical therapies.  \nKEYWORDS  \nlung cancer, nanomedicine, nanomedicine delivery system, passive targeting, active targeting  \n1 Introduction  \nLung cancer, presently, stands as the leading cancer system around the globe and in China, maintaining an alarmingly high mortality rate that prompts imminent and novel medical interventions (The, 2019; Bade and Dela Cruz, 2020) . In a world dismayed by the repercussions of the deadliest disease, it is remarkable t","cbCainH8zaqlRczb","https://ap.wps.com/l/cbCainH8zaqlRczb","pdf",1814883,16,"English","# Introduction\n## Lung cancer classifications\n## Conventional therapies and chemotherapy limitations\n## Rationale for nanomedicine strategies","[{\"question\":\"Why are conventional lung cancer therapies limited in effectiveness?\",\"answer\":\"Conventional therapies show substantial side effects and toxicities and often lack specificity, with chemotherapy used in most cases but still presenting major drawbacks and resistance-related issues.\"},{\"question\":\"What advantages do nanomedicines provide for lung cancer treatment?\",\"answer\":\"Nanomedicines can enhance drug delivery to tumor sites, extend drug half-life, and reduce unintended toxic effects on healthy tissues, supporting earlier detection and more targeted therapy.\"},{\"question\":\"How do active and passive targeting nanomedicine strategies differ?\",\"answer\":\"Active targeting focuses on a single target, which can yield unsatisfactory outcomes, while passive targeting often suffers from limited delivery rates; combining the two is suggested to improve concentration at target sites.\"}]","Moving beyond traditional therapies - the role of nanomedicines in lung cancer - Review | PDF",1789975904]